Clarus Ventures’s VBI Vaccines, Inc. New Common Stock (Canada) VBIV Stock Holding History

Clarus Ventures’s Portfolio VBIV Stock Details VBIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	$6.51M	Hold	89,701	–	–	1.53%	8
2018 Q2	$7.4M	Hold	89,701	–	–	2.63%	6
2018 Q1	$9.42M	Hold	89,701	–	–	9.63%	4
2017 Q4	$11.5M	Hold	89,701	–	–	11.44%	4
2017 Q3	$10.4M	Hold	89,701	–	–	8.43%	3
2017 Q2	$11.7M	Hold	89,701	–	–	10.76%	3
2017 Q1	$14.8M	Hold	89,701	–	–	11%	3
2016 Q4	$8.34M	Hold	89,701	–	–	5.49%	5
2016 Q3	$9.23M	Hold	89,701	–	–	5.67%	5
2016 Q2	$10.6M	Sell	89,701 -82,733	-48%	-$8.29M	9.3%	4
2016 Q1	$12.2M	Buy	172,434 +6,731	+4%	+$445K	9.13%	5
2015 Q4	$12.1M	Hold	165,703	–	–	8.5%	5
2015 Q3	$13.1M	Hold	165,703	–	–	7.55%	5
2015 Q2	$13.3M	Hold	165,703	–	–	5.86%	5
2015 Q1	$12.9M	Hold	165,703	–	–	5.37%	6
2014 Q4	$16.6M	Hold	165,703	–	–	4.73%	7
2014 Q3	$16.3M	Buy	+165,703	New	+$18.3M	6.51%	6

Other funds holding VBIV

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return

MIH

Meitav Investment House Bene-Beraq, Israel $14.9B AUM 46.8% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

Altshuler Shaham Tel Aviv, Israel $8.04B AUM 44.04% 1-Year Est. Return

GAI

General American Investors New York $1.69B AUM 40.94% 1-Year Est. Return

Clarus Ventures's VBIV Position: Q3 2018 in Review

Clarus Ventures held its VBI Vaccines, Inc. New Common Stock (Canada) (VBIV) position steady in Q3 2018 at 89,701 shares worth $6.51M. The position accounts for 1.53% of the portfolio, ranked #8.

Clarus Ventures first reported a position in VBIV in Q3 2014 and has held it in 17 quarters since. The position peaked at $16.6M in Q4 2014. 40 funds tracked by Wall St. Rank hold VBIV as of Q3 2018.

Clarus Ventures held 89,701 shares of VBI Vaccines, Inc. New Common Stock (Canada) worth $6.51M as of Q3 2018.
Clarus Ventures left its VBI Vaccines, Inc. New Common Stock (Canada) share count unchanged in Q3 2018.
VBI Vaccines, Inc. New Common Stock (Canada) made up 1.53% of Clarus Ventures's portfolio in Q3 2018, its #8 holding.
Clarus Ventures first reported a position in VBI Vaccines, Inc. New Common Stock (Canada) in Q3 2014 and has held it in 17 quarters since.
Clarus Ventures's VBI Vaccines, Inc. New Common Stock (Canada) position peaked at $16.6M in Q4 2014.
40 funds tracked by Wall St. Rank held VBI Vaccines, Inc. New Common Stock (Canada) as of Q3 2018.

Based on Clarus Ventures's 13F filing for Q3 2018, filed 14 Nov 2018.